drugset
drugset / Trial / NCT06610890

Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets

NCT06610890 ↗

Phase 1 Completed 20 enrolled Ganzhou Hemay Pharmaceutical Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

1. To evaluate the pharmacokinetics of Hemay005 tablets on midazolam and its active metabolite α-hydroxymidazolam after multiple administration; 2. Evaluate the effect of Hemay005 tablet on QT interval; 3. To investigate the effect of Hemay 005 tablets on inflammatory factors.

Timeline

Start
2024-12-12
Primary completion
2025-01-20
Completion
2025-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject MUFEMILAST Small molecule 60 mg Oral
Subject Midazolam Small molecule 15 mg Oral

Indications

psoriasis